Balchem Corporation (BCPC)
NEUTRAL基本面
71
价格
$179.24
市值
$5.79B
第一部分 · 这家公司值多少
概览
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
资产负债表与流动性
营收
$1.09B
最近12个月(截至2026/6/30)
净利润
$164M
最近12个月(截至2026/6/30)
自由现金流
-
股东权益合计
$1.26B
负债合计
$429M
流动比率
2.66
利息覆盖率
-
债务/EBITDA
0.65
每股收益
营收与净利润
自由现金流
收入构成
历史财务表
利润率变化
债务变化
债务负担有多重
增长一览表
增长 — 营业收入
公允价值估算
公允价值
$126.59
当前价格
$179.24
安全边际
-41.6%
公允价值区间
$82.29 - $170.90
估算方法
估值指标
市盈率(P/E)
34.87
ROE
12.3%
市净率(P/B)
4.34
P/FCF
-
毛利率
36.3%
ROIC
10.9%
盈利能力雷达图
Value Creation (Economic Moat)
ROIC
10.9%
WACC
9.0%
ROIC − WACC
+2.0 pp
ROIC exceeds the cost of capital — the company is creating value for shareholders.
基本面分析标准
通过(17)
- EPS shows upward trend
- EPS CAGR 10.73%
- Price CAGR 8.01%
- ROIC 11.0%
- Gross Margin 36.3%
- Debt/Equity ratio
- Operating Margin 20.2%
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- ROE 12.8%
- Revenue Growth 5Y 8.1%
- Analyst Consensus 78% Buy
- Earnings Quality (OCF/NI) 1.34
- Share Dilution -0.3%
- Net Margin Trend 15.1% vs 14.5%
- Piotroski F-Score 9/9
未通过(6)
- P/B Ratio 4.34
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Earnings Surprise avg 0.9%
- PEG Ratio 2.72
不可用(5)
- P/FCF NaN
- Dividend Payout NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
Piotroski F-评分
财务状况强健
盈利质量
高质量:盈利有现金流支撑
股权稀释
正在回购股份,对股东友好
公司治理
管理团队
| 姓名 | 职位 | 年龄 |
|---|---|---|
| Mr. Theodore Lee Harris | CEO, President & Chairman | 60 |
| Mr. Carl Martin Bengtsson | Executive VP, CFO, Treasurer and GM of Animal Nutrition & Health | 48 |
| Ms. Hatsuki Miyata J.D. | Executive VP, Chief Legal Officer & Secretary | 49 |
| Mr. M. Brent Tignor | Senior VP & Chief Human Resources Officer | 47 |
| Mr. Frederic Boned | Senior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health | 46 |
| Ms. Erin L. Gilson | VP & Chief Accounting Officer | - |
| Mr. Martin Luther Reid | Senior VP & Chief Supply Chain Officer | 58 |
| Mr. Job L. van Gunsteren | Senior VP & GM of Specialty Products | 48 |
| Mr. George Graham | Senior VP and Chief R&D Officer | 55 |
审计风险
3
董事会风险
4
薪酬风险
4
股东权利风险
7
第二部分 · 价格与买入时机
这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。
Latest News
Recent headlines for BCPC, sourced from Markets Gazette.